Searle & Co’s Xeris Biopharma Holdings XERS Stock Holding History

Searle & Co’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,000	Closed	-$51K	–	158
2022 Q1	$51K	Hold	20,000	–	–	0.02%	152
2021 Q4	$59K	Hold	20,000	–	–	0.02%	156
2021 Q3	$49K	Buy	+20,000	New	+$58.1K	0.02%	144
2021 Q2	–	Sell	-21,500	Closed	-$97K	–	151
2021 Q1	$97K	Sell	21,500 -12,500	-37%	-$67.4K	0.04%	137
2020 Q4	$167K	Buy	+34,000	New	+$170K	0.08%	134
2020 Q3	–	Sell	-69,000	Closed	-$148K	–	146
2020 Q2	$148K	Buy	69,000 +17,000	+33%	+$59.2K	0.09%	128
2020 Q1	$101K	Buy	+52,000	New	+$224K	0.07%	120

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Searle & Co's XERS Position: Q2 2022 in Review

Searle & Co sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 20,000 shares — an estimated $51K sold.

Searle & Co first reported a position in XERS in Q1 2020 and held it in 7 quarters. The position peaked at $167K in Q4 2020. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

Searle & Co reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
Searle & Co sold 20,000 Xeris Biopharma Holdings shares in Q2 2022, an estimated $51K.
Searle & Co first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 7 quarters.
Searle & Co's Xeris Biopharma Holdings position peaked at $167K in Q4 2020.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on Searle & Co's 13F filing for Q2 2022, filed 3 Aug 2022.